MITOZANTRONE AS SINGLE AGENT THERAPY IN HEPATOCELLULAR-CARCINOMA - A PHASE-II STUDY

被引：22

作者：

DUNK, AA

SCOTT, SC

JOHNSON, PJ

MELIA, W

LOK, ASF

MURRAYLYON, I

WILLIAMS, R

THOMAS, HC

机构：

[1] UNIV LONDON KINGS COLL HOSP,SCH MED,LIVER UNIT,LONDON SE5 8RX,ENGLAND

[2] CHARING CROSS HOSP,SCH MED,LONDON W6 8RF,ENGLAND

[3] CYANAMID INT RES CTR,RICHMOND TW9 1PJ,SURREY,ENGLAND

来源：

关键词：

D O I：

10.1016/S0168-8278(85)80777-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：395 / 404

页数：10

共 32 条

[1] ADAMSON RH, 1974, CANCER CHEMOTH REP 1, V58, P293
[2] PHASE-I CLINICAL-TRIAL OF MITOXANTRONE - A NEW ANTHRACENEDIONE ANTI-CANCER DRUG
ALBERTS, DS
GRIFFITH, KS
GOODMAN, GE
HERMAN, TS
MURRAY, E
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 5 (01) : 11 - 15
[3] SERIAL ASSESSMENT OF DOXORUBICIN CARDIOTOXICITY WITH QUANTITATIVE RADIONUCLIDE ANGIOCARDIOGRAPHY
ALEXANDER, J
DAINIAK, N
BERGER, HJ
GOLDMAN, L
JOHNSTONE, D
REDUTO, L
DUFFY, T
SCHWARTZ, P
GOTTSCHALK, A
ZARET, BL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (06) : 278 - 283
[4] BAKER LH, 1977, CANCER TREAT REP, V61, P1595
[5] CHLEBOWSKI RT, 1981, CANCER, V48, P1088, DOI 10.1002/1097-0142(19810901)48:5<1088::AID-CNCR2820480507>3.0.CO
[6] 2-W
[7] MITOXANTRONE HYDROCHLORIDE IN LYMPHOMA
COLTMAN, CA
MCDANIEL, TM
BALCERZAK, SP
MORRISON, FS
VONHOFF, DD
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 73 - 76
[8] CLINICAL SAFETY AND TOLERANCE OF MITOXANTRONE (NOVANTRONE)
CROSSLEY, RJ
[J]. CANCER TREATMENT REVIEWS, 1983, 10 : 29 - 36
[9] DOLL R, 1970, UNIO INT CANCRUM, V2
[10] FALKSON G, 1978, CANCER, V42, P2149, DOI 10.1002/1097-0142(197811)42:5<2149::AID-CNCR2820420510>3.0.CO